The global Plasma Therapy Market is valued at USD 359.8 Billion in 2022 and is projected to reach a value of USD 653.5 Billion by 2030 at a CAGR (Compound Annual Growth Rate) of 13.9% between 2023 and 2030.
A new Analysis demonstrates convalescent plasma can be used as a successful and affordable treatment in the unavoidable future pandemics, as it was used during the COVID-19 pandemic. One of the well-known therapeutic regimens for treating infectious diseases without specific treatment or vaccines is convalescent Plasma Therapy (CPT). Numerous studies support this therapy's clinical effectiveness in managing bacterial and viral infections. Convalescent Plasma Therapy with high antibody levels was granted emergency approval from the U.S. Food and Drug Administration (FDA) to treat COVID-19. Beyond just COVID-19, Plasma Therapy has demonstrated remarkable success in the treatment of several medical conditions. For instance, according to a study by the American Red Cross, Plasma Therapy showed an impressive success rate of 78% in treating patients with thrombotic thrombocytopenic purpura (TTP). In a different clinical trial, Plasma Therapy showed a 60% decrease in mortality rates for Guillain-Barré syndrome patients. Additionally, clinical trials have shown that Plasma Therapy effectively treats autoimmune diseases like lupus and arthritis, with an average improvement rate of 70% in patients. These successes demonstrate Plasma Therapy's vast potential to transform medical procedures.
Plasma Therapy Market Size, 2022 To 2030 (USD Billion)
Recent advances in Plasma Therapy have shown encouraging outcomes. According to studies, the transfusion of convalescent plasma rich in neutralizing antibodies can lessen the severity of symptoms and speed up healing. It is crucial to remember that extensive clinical trials are still being conducted to confirm the effectiveness and security of this strategy. Plasma Therapy is being investigated for treating burns, traumatic injuries, autoimmune disorders, hematological diseases, and more. The market for plasma collection and processing businesses has become more competitive due to increased demand for plasma products. The Plasma Therapy market has also undergone a revolution thanks to the development of cutting-edge technologies and methods. For instance, by removing potential pathogens, pathogen reduction technologies ensure the safety of products made from plasma. In conclusion, the Plasma Therapy market is poised for significant growth due to its potential to treat various diseases and conditions.
- The pure PRP segment is estimated to account for the largest global Plasma Therapy market share in 2023. Additionally, the increase in government financing for R&D initiatives in the sector is anticipated to fuel market expansion further.
- In 2022, the Hospital segment contributed more than 46% of the total revenue.
- North America Plasma Therapy market held over 42.9% revenue share in 2022.
Top Market Trends
- As technology and our understanding of the human genome continue to advance, more attention is paid to treating patients according to their unique needs. This trend in Plasma Therapy is reflected in creating customized plasma-derived treatments for various indications, including oncology, immunology, and regenerative medicine.
- These developments include improvements in production methods and the creation of fresh formulations for plasma-derived goods like intravenous immunoglobulin (IVIG) and coagulation factors. The market for plasma treatment is expanding due to the increased usage of these products to treat various diseases, such as immune deficiency disorders and bleeding disorders.
- Platelet-rich plasma (PRP) therapy, which is used in Plasma Therapy, is increasingly acknowledged as an effective treatment for a variety of illnesses, including orthopedic wounds, dermatological conditions, and chronic wounds. PRP's regenerative abilities, which are aided by the high concentration of growth factors and cytokines in it, can hasten healing and encourage tissue regeneration. The Plasma Therapy market is expanding overall due to the growing demand for this non-surgical, minimally invasive treatment option.
Report Coverage & Deliverables
- Real-Time Data Updates:
- Competitor Benchmarking
- Market Trends Heatmap
- Custom Research Queries
- Market Sentiment Analysis
- Demographic and Geographic Insights
The Plasma Therapy market is subject to various economic factors that impact its growth and profitability. Firstly, healthcare policy and regulation changes can significantly affect the availability and affordability of Plasma Therapy treatments. For example, if reimbursement policies become stricter or insurance coverage for such therapies is reduced, it may limit patients' access to these treatments and subsequently impact market growth. Secondly, economic downturns or recessions can also lead to reduced healthcare spending, causing a decline in demand for Plasma Therapy. The cost of Plasma Therapy treatments and the availability of advanced technologies can also influence the market, with expensive treatments hindering adoption rates in lower-income countries or regions. Additionally, pharmaceutical companies, hospitals, and Plasma Therapy facilities collaborate to improve plasma collection and distribution networks. Conserving the growing demand for convalescent plasma will be possible through these partnerships.
The global Plasma Therapy market can be categorized on the following:
The globel Plasma Therapy market can be categorized into Type, Source, Application, End User, Region. The Market can be categorized into Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin, Leukocyte-Rich Fibrin, Hyperbaric Oxygen Therapy (HBOT), Combined Plasma Therapy with Stem Cells, Other Types based on Type. The Market can be categorized into Autologous, Allogenic based on Source. The Market can be categorized into Orthopedics, Dermatology, Hematology, Neurology, Immunology, Dental, Other Applications based on Application. The Market can be categorized into Hospitals, Clinics, Ambulatory Surgical Centers, Research Institutes, Other End-Users based on End User. The Market can be categorized into North America, Europe, Asia Pacific, Latin America, Middle East & Africa, Latin America based on Region.
Below tree is interactive. You can click the nodes to get more information.
Based on Type
The Dominating Category in the Type Segment of the Plasma Therapy Market is Platelet-Rich Plasma Therapy
Platelet-rich Plasma Therapy is the market leader in the Plasma Therapy Market's type sector. In this treatment, platelets are extracted from the patient's blood, separated, and injected directly into the afflicted area. Platelets effectively treat orthopedic injuries, chronic wounds, and hair regrowth because they contain growth factors that encourage tissue healing and regeneration. The treatment's appeal among sportsmen and patients looking for alternatives to surgical procedures is also due to how less intrusive it is. Using a PRP injection for shoulder pain brought on by rotator cuff tears, Achilles tendon ruptures, and other soft-tissue injuries is becoming more popular because platelet-rich plasma has been found to speed up the healing process significantly.
Based on Source
This Method Ensures a Higher Safety Profile as it Eliminates the Risk of Transmitting Infections or Adverse Reactions
Autologous source using a patient's blood plasma for treatment is typically the dominant category in the source segment of the Plasma Therapy market. Since autologous Plasma Therapy uses the patient's blood as the source of the treatment, there is a lower chance of infections or other side effects. It also does away with the requirement for outside donors, making it a safer and more long-term strategy. Platelet-rich plasma (PRP) is used in orthopedic procedures like joint regeneration or sports injuries and cosmetic procedures like skin rejuvenation, as examples of autologous Plasma Therapy.
Based on Application
With its High Effectiveness and Minimal Side Effects, Orthopedics remains The Leading Segment in the Plasma Therapy Market.
Orthopaedics is the most popular application segment of the Plasma Therapy market. Plasma Therapy is used in orthopedics to treat various musculoskeletal conditions, including osteoarthritis, tendinopathy, and muscle injuries. For instance, platelet-rich plasma (PRP) therapy is now widely used to treat joint pain and injuries. PRP is created by isolating platelets from the patient's blood and injecting them directly into the affected area to promote tissue repair and regeneration. The orthopedic application of Plasma Therapy is the market leader in the application segment due to its promising outcomes in easing pain, enhancing joint function, and hastening the healing process.
Based on End-User
The Increasing Burden of Chronic Diseases and Rising Demand for Advanced Treatment Options Have Led to The Expansion of Hospitals and Clinics
In the Plasma Therapy market, hospitals and clinics hold most of the end-user market. These facilities have the knowledge and tools required to carry out Plasma Therapy securely and efficiently. Additionally, the proliferation of hospitals and clinics has fueled the market's expansion due to the increased burden of chronic diseases and the need for cutting-edge treatment alternatives.
Based on Region
The Market is Expanding in North America Due to an Increase in Plasma Collecting Facilities, Biotechnology Research Facilities, and Increased Plasma Therapy Acceptance Rates
The Plasma Therapy Market is the largest in the world, with most of the market share coming from North America. The region’s dominant position is attributable to the existence of major market participants, the development of healthcare infrastructure, high disposable income, and the rising incidence of chronic diseases such as cancer, autoimmune diseases, and blood disorders. The market is expanding in North America due to increased plasma collecting facilities, biotechnology research facilities, and Plasma Therapy acceptance rates.
The strong healthcare system in North America supports adopting and applying Plasma Therapy. Hospitals, clinics, and research facilities in the area are well-equipped and have the equipment and knowledge needed to carry out clinical trials and offer plasma-based therapies. This infrastructure makes it easier to market and distribute plasma-derived therapies, which expands their market in North America. Additionally, the area has a robust regulatory system that guarantees the security and effectiveness of Plasma Therapy products. To ensure the integrity of the market and promote investor confidence, regulatory bodies, like the Food and Drug Administration (FDA) in the United States, have established strict guidelines for the approval and monitoring of plasma-derived therapies. Through inspections of the manufacturing facilities and post-market monitoring, the FDA monitors plasma products' security and caliber. If they discover any safety issues or legal violations, they can take regulatory action, such as sending out warning letters or starting product recalls. Moreover, the COVID-19 pandemic has raised the need for plasma-derived products to create vaccinations and treatments.
The North American region is anticipated to maintain its dominance in the plasma treatment market in the coming years due to technological developments, rising research and development efforts, and an expanding patient population with chronic diseases.
Numerous international and regional actors compete fiercely on the global market. Major corporations engage in strategic alliances, mergers & acquisitions, and joint ventures to acquire a market advantage. In addition, manufacturers concentrate on capacity expansions and R&D for new product development to offer consumers products that are on trend. Companies are investing in new technology to enhance plasma collection and processing techniques. For instance, Terumo BCT created the effective plasma separation and collection Spectra Optia Apheresis System. To streamline the Plasma Therapy process and ensure higher product quality and scalability, businesses are also investigating the use of automation and robotics.
The key players in the global Plasma Therapy market include - Cambryn Biologics LLC (U.S.), BioLife Plasma Services (U.S.), CSL Ltd. (Australia), Biotest Pharmaceuticals (Germany), Kedrion S.P.A. (Italy), Grifols International S.A. (Spain), China Biologic Products Inc. (China), LFB Plasma (U.S.), Octapharma Plasma Inc. (Switzerland) among others.
Recent Market Developments
- On March 23, 2023, the construction of a new facility for plasma-derived therapies was funded by Takeda's largest manufacturing capacity expansion investment in Japan; Takeda intends to construct a brand-new manufacturing facility for plasma-derived therapies (PDTs) in Osaka, Japan, with an estimated £600 million in investment.
- On September 8, 2022, to supply consistent, high-quality cellular starting material for use in the production of life-saving cellular therapies, Cryoport, Inc., a leader in temperature-controlled supply chain solutions for the life sciences industry, today announced it has entered into a strategic partnership with BioLife Plasma Services, a division of the multinational biopharmaceutical company Takeda.
- On November 15, 2022, with an investment of Tk 5,000 crore, the Chinese company Sinovac Biotech, which manufactures the COVID-19 vaccine, will begin manufacturing Plasma-Derived Medical Products (PDMP) in Bangladesh.
Segmentation of the Global Plasma Therapy Market
- Type (Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin, Leukocyte-Rich Fibrin, Hyperbaric Oxygen Therapy (HBOT), Combined Plasma Therapy with Stem Cells, Other Types)
- Source (Autologous, Allogenic)
- Application (Orthopedics, Dermatology, Hematology, Neurology, Immunology, Dental, Other Applications)
- End User (Hospitals, Clinics, Ambulatory Surgical Centers, Research Institutes, Other End-Users)
- Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa, Latin America)
|Regions & Countries Covered
- North America - (U.S., Canada, Mexico)
- Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe)
- Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific)
- Latin America - (Brazil, Argentina, Rest Of Latin America)
- Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
- Cambryn Biologics LLC (U.S.)
- BioLife Plasma Services (U.S.)
- CSL Ltd. (Australia)
- Biotest Pharmaceuticals (Germany)
- Kedrion S.P.A. (Italy)
- Grifols International S.A. (Spain)
- China Biologic Products Inc. (China)
- LFB Plasma (U.S.)
- Octapharma Plasma Inc. (Switzerland)
||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST
analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market
attractiveness analysis by segments and North America, company market share analysis, and COVID-19
Pricing and purchase options
||Avail of customized purchase options to meet your exact research needs. Explore purchase options